Plasma-lyte

Plasma-Lyte is a crystalloid solution for intravenous infusion, with varying electrolyte formulation depending on market. Generally the solution has a composition that mimics human physiological plasma electrolyte concentrations, osmolality and pH.[1]

It is available as a generic medication.[2][3]

Plasma-lyte 148 (pH7.4)

Plasma-Lyte 148 is a market-specific solution available in the United Kingdom and Australia, among others and has the following composition:

Sodium 140 mmol/L
Potassium 5 mmol/L
Magnesium 1.5 mmol/L
Chloride 98 mmol/L
Acetate 27 mmol/L
Gluconate 23 mmol/L

This solution is manufactured and marketed by Baxter International Inc.[4]

References
  1. 1: Rizoli S. PlasmaLyte. J Trauma. 2011 May;70(5 Suppl):S17-8. doi: 10.1097/TA.0b013e31821a4d89. PMID 21841561.
  2. "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
  3. "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  4. 2: Baxter. Plasma-Lyte 148 product information. 2013. available at URL: http://www.baxterhealthcare.com.au/downloads/healthcare_professionals/cmi_pi/plasmalyte148_pi.pdf Archived 23 June 2017 at the Wayback Machine
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.